Anti-VEGF agents have revolutionised outcomes for people with age-related macular degeneration (AMD) but nonadherence with the frequent injections needed and the monitoring required is a significant issue. New drugs are being developed that require fewer treatments, thereby improving treatment efficacy and reducing disease burden.
Age-related macular degeneration (AMD) is the leading cause of severe vision loss in our community and is the cause of blindness in about 50% of Australians who are legally blind.1 Intravitreally injected anti-vascular endothelial growth factor (anti-VEGF) drugs have significantly reduced blindness due to AMD complicated by choroidal bleeding. Unfortunately, the burden of continued monitoring and treatment and the economic costs associated with therapy for the patient and the Australian healthcare system have also increased significantly. Newer drugs and delivery systems and different treatment regimens are being investigated in the hope of being able to overcome these challenges.
Picture credit: © BSIP/medicalimages.com